Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zhebin Dong"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Metabolic factors play a critical role in the development of digestive system cancers (DSCs), and East Asia has the highest incidence of malignant tumors in the digestive system. We performed a two-sample Mendelian randomization analysis to
Externí odkaz:
https://doaj.org/article/f7166b2f75f04bddbc108b1f19cd573d
Autor:
Hanting Xiang, Zhebin Dong, Hengmiao Wu, Yicheng He, Zhengwei Chen, Sangsang Chen, Weiming Yu, Chao Liang
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background The D2 procedure has been accepted as the standard treatment for advanced gastric cancer (GC) in East Asia. Determination of the number of lymph nodes (LNs) after gastrectomy may influence the pathological stage assessment of lymp
Externí odkaz:
https://doaj.org/article/9397f1f5eaf94f8eb4377715092282e1
Autor:
Xianlei Cai, Xueying Li, Chao Liang, Miaozun Zhang, Yuan Xu, Zhebin Dong, Yihui Weng, Weiming Yu
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Mitochondrial DNA plays a critical role in the pathophysiological process of inflammation. However, the relationship between mitochondrial DNA copy number (mtDNA-CN) and inflammatory bowel diseases (IBD) remains poorly understood. We conduct
Externí odkaz:
https://doaj.org/article/ddb564bcd7be4938969d35a236ca9bb5
Autor:
Zhebin Dong, Hanting Xiang, Hengmiao Wu, Zhengwei Chen, Sangsang Chen, Yicheng He, Hong Li, Weiming Yu, Chao Liang
Background: Lymph node (LN) status is vital to indicate and evaluate the curative potential of relatively early gastric cancer (GC; T1–T2) treatment (endoscopic or surgery). Currently, there is a lack of robust and convenient methods to identify su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8fc48baebe51aaeb1f9ab1c3775ff56
https://doi.org/10.21203/rs.3.rs-2618696/v1
https://doi.org/10.21203/rs.3.rs-2618696/v1
Autor:
Zhebin Dong, Hong Li, Weiming Yu, Jie Shen, Xianlei Cai, Wei Chen, Miaozun Zhang, Chao Liang, Yuan Xu
Publikováno v:
Cell Death & Disease
Sorafenib, a multikinase inhibitor, is considered as the only approved drug to cure the advanced hepatocellular carcinoma (HCC); however, the acquired chemoresistance caused by intratumoral hypoxia through sorafenib long term therapy induces sorafeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5321b19bfbbe865e78a5f176e5574d1
http://europepmc.org/articles/PMC7701149
http://europepmc.org/articles/PMC7701149